Lack of association of FKBP5 SNPs and haplotypes with susceptibility and treatment response phenotypes in Han Chinese with major depressive disorder: A pilot case-control study (STROBE).
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
10 Sep 2021
10 Sep 2021
Historique:
received:
14
12
2020
accepted:
27
07
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
21
9
2021
Statut:
ppublish
Résumé
The identification of single-nucleotide polymorphisms (SNPs) in genes putatively related to pathophysiological processes in major depressive disorder (MDD) might improve both diagnosis and personalized treatment strategies eventually leading to more effective interventions. Considering the important role of the glucocorticoid receptor and the related FK506 binding protein 51 (FKBP51) in the pathophysiology of MDD, we aimed to investigate putative associations between variants of FKBP5, the coding gene of FKBP51, with antidepressant treatment resistance and MDD susceptibility.Nine common SNPs of the FKBP5 gene prioritized based on location and, putative or known functions were genotyped in Han Chinese population, including MDD patients with or without antidepressant-treatment resistance and healthy controls. Associations of FKBP5 SNPs with MDD susceptibility and treatment response were examined in the whole group of MDD patients, as well as in subgroups stratified by antidepressant treatment resistance, compared with healthy controls.In total, 181 Han Chinese patients with MDD and 80 healthy controls were recruited. No significant SNP or haplotype associations were observed in the whole patient group. There were nominal significant differences both for the haplotype block with SNPs in strong LD (r2 > 0.8, P = .040) and haplotype block with SNPs in moderate LD (r2 > 0.1, P = .017) between the haplotype distributions of patients with antidepressant treatment resistance (n = 81) and healthy controls, but both significances did not survive multiple testing correction. Furthermore, no specific haplotype could be observed causing a significant difference in any combination between all comparisons.No associations were observed of FKBP5 variants with MDD or antidepressant treatment response. The lack of associations might be due to the relatively small sample size of this study (power ranged from 0.100 to 0.752). A follow-up study will need larger, better phenotyped, and more homogeneous samples to draw a definitive conclusion regarding the involvement of this gene in MDD.
Identifiants
pubmed: 34516490
doi: 10.1097/MD.0000000000026983
pii: 00005792-202109100-00005
pmc: PMC8428740
doi:
Substances chimiques
Tacrolimus Binding Proteins
EC 5.2.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e26983Subventions
Organisme : tianjin key programs for prevention and treatment of chronic diseases
ID : 17ZXMFSY00070
Organisme : tianjin natural science foundation
ID : 16JCYBJC24200
Organisme : tianjin key discipline project for psychiatry
ID : XXXX XXXX
Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
WHO. Depression. WHO. Available at: http://www.who.int/mediacentre/factsheets/fs369/en/ . Published 2017. Updated February 2017. Accessed.
Rotenstein LS, Ramos MA, Torre M, et al. Prevalence of depression, depressive symptoms, and suicidal ideation among medical students: a systematic review and meta-analysis. JAMA 2016;316:2214–36.
Dunner DL, Rush AJ, Russell JM, et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry 2006;67:688–95.
Wohleb ES, Franklin T, Iwata M, Duman RS. Integrating neuroimmune systems in the neurobiology of depression. Nature Rev Neurosci 2016;17:497–511.
Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009;65:732–41.
Himmerich H, Binder EB, Kunzel HE, et al. Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol Psychiatry 2006;60:882–8.
Kiecolt-Glaser JK, Derry HM, Fagundes CP. Inflammation: depression fans the flames and feasts on the heat. Am J Psychiatry 2015;172:1075–91.
Denny WB, Valentine DL, Reynolds PD, Smith DF, Scammell JG. Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. Endocrinology 2000;141:4107–13.
Sabbagh JJ, O’Leary JC 3rd, Blair LJ, et al. Age-associated epigenetic upregulation of the FKBP5 gene selectively impairs stress resiliency. PLoS One 2014;9:e107241.
Tatro ET, Everall IP, Kaul M, Achim CL. Modulation of glucocorticoid receptor nuclear translocation in neurons by immunophilins FKBP51 and FKBP52: implications for major depressive disorder. Brain Res 2009;1286:01–12.
Binder EB. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 2009;34: (suppl 1): S186–95.
Pei H, Li L, Fridley BL, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009;16:259–66.
Yao JJ, Zhao QR, Lu JM, Mei YA. Functions and the related signaling pathways of the neurotrophic factor neuritin. Acta Pharmacol Sin 2018;39:1414–20.
Kin K, Yasuhara T, Kawauchi S, et al. Lithium counteracts depressive behavior and augments the treatment effect of selective serotonin reuptake inhibitor in treatment-resistant depressed rats. Brain Res 2019;1717:52–9.
Wang Y, Chang T, Chen YC, et al. Quetiapine add-on therapy improves the depressive behaviors and hippocampal neurogenesis in fluoxetine treatment resistant depressive rats. Behav Brain Res 2013;253:206–11.
Kastle M, Kistler B, Lamla T, et al. FKBP51 modulates steroid sensitivity and NFkappaB signalling: A novel anti-inflammatory drug target. Eur J Immunol 2018;48:1904–14.
Hernandez-Diaz Y, Gonzalez-Castro TB, Tovilla-Zarate CA, et al. Association between FKBP5 polymorphisms and depressive disorders or suicidal behavior: a systematic review and meta-analysis study. Psychiatry Res 2019;271:658–68.
Han KM, Won E, Sim Y, et al. Influence of FKBP5 polymorphism and DNA methylation on structural changes of the brain in major depressive disorder. Bipolar Disord 2017;7:42621.
Ellsworth KA, Moon I, Eckloff BW, et al. FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet Genom 2013;23:156–66.
Cattaneo A, Gennarelli M, Uher R, et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline ’predictors’ and longitudinal ’targets’. Neuropsychopharmacology 2013;38:377–85.
Buniello A, MacArthur JAL, Cerezo M, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res 2019;47(D1):D1005–d1012.
Cai N BT, Kretzschmar W, Li Y, Liang J, Song L. Sparse whole-genome sequencing identifies two loci for major depressive disorder. Nature 2015;523:588–91.
Mullins N, Bigdeli TB, Borglum AD, et al. GWAS of suicide attempt in psychiatric disorders and association with major depression polygenic risk scores. Am J Psychiatry 2019;176:651–60.
Cai N, Bigdeli TB, Kretzschmar WW, et al. 11,670 whole-genome sequences representative of the Han Chinese population from the CONVERGE project. Sci Data 2017;4:170011.
WHO. International CLassification of Diseases-11th revision. Available at: https://wwwwhoint/classifications/icd/en/ . 2018.
Luo X, Stavrakakis N, Penninx BW, et al. Does refining the phenotype improve replication rates? A review and replication of candidate gene studies on Major Depressive Disorder and Chronic Major Depressive Disorder. Am J Med Genet B 2016;171b:215–36.
Yang C, Bosker FJ, Li J, Schoevers R. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial. BMC Psychiatry 2018;18:279.
Kang C, Shi J, Gong Y, et al. Interaction between FKBP5 polymorphisms and childhood trauma on depressive symptoms in Chinese adolescents: the moderating role of resilience. J Affect Disord 2020;266:143–50.
Brandt J, Warnke K, Jörgens S, et al. Association of FKBP5 genotype with depressive symptoms in patients with coronary heart disease: a prospective study. J Neural Transm (Vienna) 2020;127:1651–62.
Nobile B, Ramoz N, Jaussent I, et al. Polymorphisms of stress pathway genes and emergence of suicidal ideation at antidepressant treatment onset. Transl Psychiatry 2020;10:320.
Carpi FM, Di Pietro F, Vincenzetti S, Mignini F, Napolioni V. Human DNA extraction methods: patents and applications. Recent Pat DNA Gene Seq 2011;5:01–7.
Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978–89.
Galwey NW. A new measure of the effective number of tests, a practical tool for comparing families of non-independent significance tests. Genet Epidemiol 2009;33:559–68.
McGrath LM, Cornelis MC, Lee PH, et al. Genetic predictors of risk and resilience in psychiatric disorders: a cross-disorder genome-wide association study of functional impairment in major depressive disorder, bipolar disorder, and schizophrenia. Am J Med Genet B 2013;162b:779–88.
Rietschel M, Mattheisen M, Frank J, et al. Genome-wide association-, replication-, and neuroimaging study implicates HOMER1 in the etiology of major depression. Biol Psychiatry 2010;68:578–85.
Kohli MA, Lucae S, Saemann PG, et al. The neuronal transporter gene SLC6A15 confers risk to major depression. Neuron 2011;70:252–65.
Shyn SI, Shi J, Kraft JB, et al. Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. Mol Psychiatry 2011;16:202–15.
Wray NR, Pergadia ML, Blackwood DH, et al. Genome-wide association study of major depressive disorder: new results, meta-analysis, and lessons learned. Mol Psychiatry 2012;17:36–48.
Wray NR, Ripke S, Mattheisen M, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 2018;50:668–81.
Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000;157:1552–62.
Szczepankiewicz A, Narozna B, Rybakowski JK. Genes involved in stress response influence lithium efficacy in bipolar patients. Bipolar Disord 2018;20:753–60.
Lekman M, Laje G, Charney D, et al. The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR∗D) Cohort. Biol Psychiatry 2008;63:1103–10.
Velders FP, Kuningas M, Kumari M, et al. Genetics of cortisol secretion and depressive symptoms: a candidate gene and genome wide association approach. Psychoneuroendocrinology 2011;36:1053–61.
Saito S, Fujii K, Ozeki Y, et al. Cognitive function, treatment response to lithium, and social functioning in Japanese patients with bipolar disorder. Nat Genet 2017;19:552–62.
Nakamura A, Osonoi T, Terauchi Y. Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Invest 2010;1:208–11.